摘要:
Treatment of human hepatocytes with farnesoid X receptor (FXR) agonists resulted in increased expression of FGF-19. Methods of using FXR agonists to alter cell metabolism, and in pharmaceutical weight loss methods, are described.
摘要:
The use of the protein kinase “PBK” (PDZ-binding kinase) as a tumor marker in various tissue types is discussed. Methods of detecting overexpression of the protein, and kits useful therefore, are described.
摘要:
Methods for the treatment of cholestatic liver disease and reduction and prevention of hepatic injury resulting from cholestasis via administration of a FXR ligand are provided.